Nanobiotix S.A. (FRA:5NRA)
Germany · Delayed Price · Currency is EUR 16.80
-0.10 (-0.59%)
At close: Nov 28, 2025
Nanobiotix Company Description
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Nanobiotix S.A.
| Country | France |
| Founded | 2003 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 108 |
| CEO | Laurent Levy |
Contact Details
Address: 60 rue de Wattignies Paris, 75012 France | |
| Phone | 33 1 40 26 04 70 |
| Website | nanobiotix.com |
Stock Details
| Ticker Symbol | 5NRA |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Laurent Levy | Chief Executive Officer |
| Bart Van Rhijn | Chief Financial Officer |